Beijing Scitop Bio Tech Co Ltd (300858) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Beijing Scitop Bio Tech Co Ltd stock ¥7.81, price ¥13.32, that is 41.4% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ¥11.11 – ¥28.29 · fair‑value band ¥6.55 – ¥8.14 · the ¥13.32 price screens above the ¥7.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Beijing Scitop Bio Tech Co in your weekly email
Every Wednesday you see whether Beijing Scitop Bio Tech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China.
Show moreShow less
It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy relief, blood pressure regulation, and mother-infant transmission, as well as exercise, bone, heart, and skin health applications.
The company also offers microecological preparations and related application technologies for ruminants, monogastric livestock and poultry animals, aquatic animals, and pets.
In addition, it develops and promotes microbial agents, such as microbial fertilizers, bio-organic fertilizers, organic material decomposition agents, etc. for vegetable, fruit, edible fungus, forage grass, and crop planting.
Beijing Scitop Bio-tech Co., Ltd. was founded in 2003 and is headquartered in Beijing, China.
Stock analysis
Beijing Scitop Bio Tech Co Ltd (300858) currently trades at ¥13.32, while our model-based Fair Value estimate is ¥7.81, 41% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥6.27 per share, and 1 of the 15 models we run sit above the ¥13.32 price.
Bear case: the Dividend Discount group reads lowest at ¥1.73, and 14 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥6.55 (bear) to ¥8.14 (bull), the price of ¥13.32 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Beijing Scitop Bio Tech Co Ltd reported revenue of 366M CNY in FY2025 versus 365M CNY in FY2021, a compound +0.1%/yr. Reported net income was 94.5M CNY in FY2025, compounding −3.6%/yr from FY2021.
Key figures
Market cap 3.5B CNY (≈ $527M) Small · P/E ratio 63.4 · P/S ratio 16.4 · EPS (TTM) ¥0.2100 · Dividend yield 0.8% · Net margin 25.8% · Return on equity 4.4% · Return on assets (EBIT) 6.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −41%, 300858 screens richer than that median.
Fair Value models
Bear¥6.55Fair Value ¥7.81Bull¥8.14
Price ¥13.32 · Downside -41.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0940 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income¥5.20¥5.20¥5.4276
EPV¥2.60¥2.93¥3.2070
ROIC Compounder¥2.60¥2.93¥3.2070
All 15 models by family
Earnings-Based
Graham-Dodd¥2.44¥5.24¥6.6666
PEG = 1.0¥0.8100¥1.16¥1.5057
EPV¥2.60¥2.93¥3.2070
Dividend Discount
Gordon GGM¥1.22¥1.78¥2.3269
DDM Multi-Stage¥1.22¥1.68¥2.1567
Multiples
P/E Multiple¥5.92¥7.89¥9.8663
P/S Multiple¥3.65¥4.86¥6.0858
P/B Multiple¥22.81¥30.41¥38.0255
EV/EBIT¥4.48¥5.85¥7.2163
EV/EBITDA¥5.11¥6.68¥8.2564
EV/Revenue¥3.31¥4.56¥5.8151
Asset-Based
NCAV (Graham)¥2.01¥3.04¥3.8052
Economic Profit
Residual Income¥5.20¥5.20¥5.4276
ROIC Compounder¥2.60¥2.93¥3.2070
Growth Earnings
Growth-Adj P/E¥4.36¥6.23¥8.0967
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+20.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
Start year 2020 (pandemic). Over 10 years: +7.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.7%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−6.7% vs 3.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.35% → 23%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 7.2%/yr over ~8Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Beijing Scitop Bio Tech Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Above median
Fair Value upside−41.4% · Above median
Profitability
Return on equity (12 months)4.4% · Above median
Return on assets4.7% · Top 25%
Net margin (12 months)21.1% · Top 25%
Operating margin (12 months)4.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)−1.4% · Below median
Dividend yield (12 months)0.8% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)63.4× · Priciest 25%
P/B1.90× · Cheaper than median
P/S (12 months)9.43× · Pricier than median
EV/EBITDA40.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)18· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)15· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Beijing Scitop Bio Tech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300858
Frequently asked questions
Is Beijing Scitop Bio Tech Co Ltd (300858) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥7.81 versus a price of ¥13.32, about 41% lower (overvalued).
What is the fair value of 300858?
Our model-based fair value for Beijing Scitop Bio Tech Co Ltd is ¥7.81 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥13.32.
What is the quality score of 300858?
Beijing Scitop Bio Tech Co Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Scitop Bio Tech Co Ltd (300858)?
Our model-based price target is the fair value of ¥7.81 (as of Nov 5, 2026) from 15 valuation models. Cautious scenario ¥6.55, optimistic scenario ¥8.14. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Scitop Bio Tech Co Ltd stock forecast for 2026?
Our models put fair value at ¥7.81, about 41% lower versus a price of ¥13.32 (overvalued). Cautious scenario ¥6.55, optimistic scenario ¥8.14. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Scitop Bio Tech Co Ltd (300858)?
Beijing Scitop Bio Tech Co Ltd reported trailing-twelve-month revenue of about 372M CNY (latest available figure, as of Nov 5, 2026).
Does Beijing Scitop Bio Tech Co Ltd pay a dividend?
Beijing Scitop Bio Tech Co Ltd currently shows a dividend yield of 0.75% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Beijing Scitop Bio Tech Co Ltd (300858) and when is the ex-dividend date?
Beijing Scitop Bio Tech Co Ltd pays a dividend of ¥0.1 per share a year, a dividend yield of 0.8%. The last ex-dividend date was Jul 10, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 47.6% of earnings. Our assessment: Token dividend. At a yield of 0.8% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.8% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Beijing Scitop Bio Tech Co Ltd (300858)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Scitop Bio Tech Co Ltd it is ¥7.81 per share (as of Nov 5, 2026), against a price of ¥13.32. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Beijing Scitop Bio Tech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 300858 trades above its calculated fair value: price ¥13.32, fair value ¥7.81, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300858?
No. The price is what the market pays today (¥13.32); the fair value is what the company's own numbers justify (¥7.81). For Beijing Scitop Bio Tech Co Ltd the two are ¥5.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Scitop Bio Tech Co Ltd worth?
The market values Beijing Scitop Bio Tech Co Ltd at about 3.5B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥13.32; our models calculate a fair value of ¥7.81 per share.
What do the bullish and bearish scenarios say about 300858?
Our models span a range for Beijing Scitop Bio Tech Co Ltd: cautious scenario ¥6.55, base ¥7.81, optimistic ¥8.14 per share (as of Nov 5, 2026, price ¥13.32). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300858?
Beijing Scitop Bio Tech Co Ltd trades at a price-to-earnings ratio of 63.4 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥7.81 is built from several models across several years. Other multiples: P/B 1.9, P/S 9.4, EV/EBITDA 40.1.
How solid is the balance sheet of Beijing Scitop Bio Tech Co Ltd (300858)?
Balance-sheet figures for Beijing Scitop Bio Tech Co Ltd (as of Nov 5, 2026): return on equity 4.4%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 300858 from its 52-week high?
Beijing Scitop Bio Tech Co Ltd trades at ¥13.32, about 47% below its 52-week high of ¥25.27 and 2% above the low of ¥13.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.81 is for.
Which stocks are comparable to Beijing Scitop Bio Tech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Scitop Bio Tech Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ¥13.32, calculated fair value ¥7.81 (−41%), Quality Score 50/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300858 calculated?
We run Beijing Scitop Bio Tech Co Ltd through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥7.81 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Beijing Scitop Bio Tech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Scitop Bio Tech Co Ltd (300858)?
The closing price on Nov 6, 2026 was ¥13.32. Our model-based fair value is ¥7.81, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Scitop Bio Tech Co Ltd right now?
The price sits above even our optimistic bull case (¥8.14). The favourable scenario is already priced in. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Beijing Scitop Bio Tech Co Ltd
How large is the market capitalisation of Beijing Scitop Bio Tech Co Ltd (300858)?
The market capitalisation of Beijing Scitop Bio Tech Co Ltd is 3.5B CNY (≈ $527M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Scitop Bio Tech Co Ltd (300858)?
The price-to-sales ratio of Beijing Scitop Bio Tech Co Ltd is 16.4 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Scitop Bio Tech Co Ltd (300858)?
Earnings per share at Beijing Scitop Bio Tech Co Ltd are ¥0.2100 (price ÷ EPS = P/E 63.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing Scitop Bio Tech Co Ltd (300858)?
The dividend yield of Beijing Scitop Bio Tech Co Ltd is 0.8% (payout 47.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing Scitop Bio Tech Co Ltd (300858)?
The net margin of Beijing Scitop Bio Tech Co Ltd is 25.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Scitop Bio Tech Co Ltd (300858)?
The return on equity (ROE) of Beijing Scitop Bio Tech Co Ltd is 4.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Scitop Bio Tech Co Ltd (300858)?
On an EBIT basis the return on assets of Beijing Scitop Bio Tech Co Ltd is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Scitop Bio Tech Co Ltd (300858)?
The operating margin of Beijing Scitop Bio Tech Co Ltd is 4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Scitop Bio Tech Co Ltd (300858)?
Revenue at Beijing Scitop Bio Tech Co Ltd is growing −1.4% versus a year earlier (3y avg −0.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing Scitop Bio Tech Co Ltd (300858)?
Earnings per share at Beijing Scitop Bio Tech Co Ltd are growing −49.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beijing Scitop Bio Tech Co Ltd (300858) generate?
The free cash flow of Beijing Scitop Bio Tech Co Ltd is −173M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beijing Scitop Bio Tech Co Ltd (300858) hold?
Beijing Scitop Bio Tech Co Ltd holds more cash than debt, 105M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Beijing Scitop Bio Tech Co Ltd in the live analysis
One click puts Beijing Scitop Bio Tech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026